vs
Side-by-side financial comparison of Claritev Corp (CTEV) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 6.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 2.5%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CTEV vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $168.4M |
| Net Profit | $-80.6M | — |
| Gross Margin | — | — |
| Operating Margin | -3.1% | 50.6% |
| Net Margin | -32.7% | — |
| Revenue YoY | 6.2% | 143.7% |
| Net Profit YoY | 41.6% | — |
| EPS (diluted) | $-4.88 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $168.4M | ||
| Q3 25 | $246.0M | $87.3M | ||
| Q2 25 | $241.6M | $82.4M | ||
| Q1 25 | $231.3M | $65.0M | ||
| Q4 24 | $232.1M | $69.1M | ||
| Q3 24 | $230.5M | $51.6M | ||
| Q2 24 | $233.5M | $73.8M | ||
| Q1 24 | $234.5M | $137.7M |
| Q4 25 | $-80.6M | — | ||
| Q3 25 | $-69.8M | $-31.3M | ||
| Q2 25 | $-62.6M | $-12.7M | ||
| Q1 25 | $-71.3M | $-40.5M | ||
| Q4 24 | $-138.0M | — | ||
| Q3 24 | $-391.4M | $-29.5M | ||
| Q2 24 | $-576.7M | $-61.9M | ||
| Q1 24 | $-539.7M | $61.0M |
| Q4 25 | -3.1% | 50.6% | ||
| Q3 25 | 4.1% | -11.4% | ||
| Q2 25 | 6.9% | 8.6% | ||
| Q1 25 | 4.2% | -34.0% | ||
| Q4 24 | -17.8% | -6.4% | ||
| Q3 24 | -146.7% | -31.0% | ||
| Q2 24 | -224.4% | 3.5% | ||
| Q1 24 | -207.4% | 52.5% |
| Q4 25 | -32.7% | — | ||
| Q3 25 | -28.4% | -35.9% | ||
| Q2 25 | -25.9% | -15.4% | ||
| Q1 25 | -30.8% | -62.2% | ||
| Q4 24 | -59.4% | — | ||
| Q3 24 | -169.8% | -57.2% | ||
| Q2 24 | -247.0% | -83.9% | ||
| Q1 24 | -230.1% | 44.3% |
| Q4 25 | $-4.88 | $0.32 | ||
| Q3 25 | $-4.23 | $-0.16 | ||
| Q2 25 | $-3.81 | $-0.06 | ||
| Q1 25 | $-4.38 | $-0.21 | ||
| Q4 24 | $-8.49 | $-0.14 | ||
| Q3 24 | $-24.25 | $-0.15 | ||
| Q2 24 | $-35.78 | $-0.33 | ||
| Q1 24 | $-33.40 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $167.9M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $-302.0M |
| Total Assets | $4.9B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $167.9M | ||
| Q3 25 | $39.2M | $92.4M | ||
| Q2 25 | $56.4M | $86.1M | ||
| Q1 25 | $23.1M | $114.6M | ||
| Q4 24 | $16.8M | $144.8M | ||
| Q3 24 | $86.6M | $144.7M | ||
| Q2 24 | $48.8M | $189.3M | ||
| Q1 24 | $58.7M | $226.6M |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $-302.0M | ||
| Q3 25 | $-101.8M | $-451.4M | ||
| Q2 25 | $-39.9M | $-433.5M | ||
| Q1 25 | $14.8M | $-426.2M | ||
| Q4 24 | $84.0M | $-388.7M | ||
| Q3 24 | $207.6M | $-370.2M | ||
| Q2 24 | $603.4M | $-344.2M | ||
| Q1 24 | $1.2B | $-294.3M |
| Q4 25 | $4.9B | $465.9M | ||
| Q3 25 | $5.0B | $364.0M | ||
| Q2 25 | $5.1B | $347.1M | ||
| Q1 25 | $5.1B | $324.0M | ||
| Q4 24 | $5.2B | $343.8M | ||
| Q3 24 | $5.3B | $314.1M | ||
| Q2 24 | $5.7B | $352.3M | ||
| Q1 24 | $6.4B | $373.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $45.2M |
| Free Cash FlowOCF − Capex | $36.4M | — |
| FCF MarginFCF / Revenue | 14.8% | — |
| Capex IntensityCapex / Revenue | 12.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $45.2M | ||
| Q3 25 | $19.9M | $-4.3M | ||
| Q2 25 | $61.2M | $-31.4M | ||
| Q1 25 | $-30.1M | $-22.6M | ||
| Q4 24 | $-33.4M | $-35.0M | ||
| Q3 24 | $72.8M | $-35.3M | ||
| Q2 24 | $18.5M | $-7.2M | ||
| Q1 24 | $49.7M | $53.8M |
| Q4 25 | $36.4M | — | ||
| Q3 25 | $-16.3M | — | ||
| Q2 25 | $36.6M | — | ||
| Q1 25 | $-68.9M | — | ||
| Q4 24 | $-63.8M | — | ||
| Q3 24 | $41.1M | $-35.5M | ||
| Q2 24 | $-7.0M | $-7.3M | ||
| Q1 24 | $19.2M | $53.8M |
| Q4 25 | 14.8% | — | ||
| Q3 25 | -6.6% | — | ||
| Q2 25 | 15.2% | — | ||
| Q1 25 | -29.8% | — | ||
| Q4 24 | -27.5% | — | ||
| Q3 24 | 17.8% | -68.7% | ||
| Q2 24 | -3.0% | -9.9% | ||
| Q1 24 | 8.2% | 39.0% |
| Q4 25 | 12.1% | 0.0% | ||
| Q3 25 | 14.7% | 0.0% | ||
| Q2 25 | 10.2% | 0.0% | ||
| Q1 25 | 16.8% | 0.0% | ||
| Q4 24 | 13.1% | 0.0% | ||
| Q3 24 | 13.8% | 0.3% | ||
| Q2 24 | 10.9% | 0.1% | ||
| Q1 24 | 13.0% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
